- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05175703
Post-market Registry to Assess the Clinical Performance and Safety of the Passeo-18 Lux in Infrainguinal Arteries
A Prospective, Multi-centre, Sinlge Arm, Post-market Registry to Assess the Clinical Performance and Safety of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries
The purpose of his study is to collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
Research institute for enrollment, and period; It is planned to enroll about 200 subjects in 9 domestic research institutes. It is expected to require about 12-18 months to enroll the subjects.
Subject follow-up schedule; Perform follow-up by phone call or clinical assessment at 1, 6, 12, and 24 months of the postoperative time point
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, single arm, post-market registry subject to all the patient group with the relevant indications, where follow-up is performed in 1, 6, 12 (including angio follow up), and 24 month. The Passeo-18 Lux DCB including all the target patient group, is subject to every disease requiring revascularization in the infrainguinal arteries and is going to use the Passeo-18 Lux DCB.
The subject will receive percutaneous intervention using Passeo-18 Lux DCB according to the standard care guideline of this hospital. All complications and adverse events occurring during the operation will be recorded thoroughly. During the intervention, the number of lesions to be treated with Passeo-18 Lux will be determined carefully under judgment of the PI (When using more than one Passeo-18 Lux in a patient, maximum drug release recommended in the IFU should be considered.) The target lesion which is compose of one or several small lesions treatable with a balloon catheter is defined as a "treatment segment". The results of all the lesions treated with Passeo-18 Lux for the first time (regardless of which side limb) are going to be documented in eCRF, through which final results will be analyzed. All complications and adverse events from the intervention will be recorded thoroughly and reported to IRB according to the prescribed form.
Stent insertion into the lesion finishing treatment with drug coated balloon catheter will be determined by the study physician. For the subjects follow-up via phone call or clinical assessment will be conducted under below schedule. In this study the subjects who require stent insertion will not be classified as treatment failure. Before discharge of the subjects, medical prescription will follow the standard of care of this hospital, which will be documented. All the postoperative complications and adverse events will be recorded thoroughly and reported to IRB via suitable form. The subjects will be administered with proper anticoagulant, antiplatelet drug, and blood vessel dilator according to common and standard care guideline. The treatment follows the guideline described in IFU of Passeo-18 Lux DCB.
A subject does not have to participate in this study for treatment of the stenosed lower limb blood vessel. For example, there are a lot of devices available for treatment of the subject, including standard drug coated balloon, laser, and stent. The study physician will provide sufficient explanation on these alternative therapies for his/her understanding. Even though a subject decided not to participate in this study, it would not affect current and future treatment that he/she receives.
As the subjects of this study participate in in this study voluntarily according to their own will, they can discontinue the participation without any disadvantage or limitation at any time when they desire. They will not receive any disadvantage in later treatment from that. However the information collected during participation may be able to be used as it was anonymized. When a subject discontinued participation of study early, the participation should be terminated after completing preparation of eCRF as soon as possible. Also, The principal investigator regards a case as failure in follow-up of a subject up to for 24 months. In failing the follow-up, the principal investigator should record the failure of follow-up on the CRF.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kyunggi
-
Suwon, Kyunggi, Korea, Republic of, 16499
- Ajou University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Person over 19 years old who is recognized as an adult in the civil law
- Person willing to sign a subject written consent
- Patient having infrainguinal arterial lesion that is adequate to intravascular treatment using Passeo-18 Lux Paclitaxel releasing Balloon Catheter
- Peripheral arterial disease in 2-5 grade of Rutherford
- Patient without at least one of significant lesions (≥50% of stenosis) in distal leaking artery. When there is at least one of opening blood vessels under the knee in treatment of arterial popliteal or at least one of opening cural vessel under the ankle in arterial treatment under the knee. Treatment of inflow arterial disease is allowed before the relevant treatment.)
Exclusion Criteria:
- Life expectancy ≤ 1 year
- Patient who is currently under medication of an investigation drug or treatment by a device that did not reach the primary endpoints.
- Subject during pregnancy or having a plan of pregnancy during the study period
- A guide wire could not passed into the target lesion (Successful passage of guide wire means its movement into the distal part of target lesion without causing arterial dissection or perforation by the end of guidewire.)
- Acute thrombosis is accompanied
- Major amputation is planned There is medical history of bypass surgery on target vessel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: the infrainguinal arteries disease group
Actual patient group with any atherosclerotic change in the infrainguinal arteries
|
collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical primary endpoints
Time Frame: 30 days
|
No occurrence of Major Adverse Event (MAE); No death or lower limb amputation in the subject from the index procedure for 30 days
|
30 days
|
Clinical primary endpoints
Time Frame: 6 months
|
No occurrence of Major Adverse Event (MAE); No target vessel revascularization (TVR) within 6 months from index procedure.
|
6 months
|
Functional primary endpoints
Time Frame: 12 months
|
No target lesion revascularization (TLR) (a case showing at least 50% stenosis in visual inspection of target vessel in the patient with any recurred symptom) is needed clinically for 12 months after operation.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TLR (Target Lesion Revascularzation) rate
Time Frame: 6-24 months
|
ratio of TLR patients among full cohort within 6 ~ 24 months
|
6-24 months
|
TVR rate
Time Frame: 6-24 months
|
ratio of TVR patients among full cohort within 6 ~ 24 months
|
6-24 months
|
Survival without amputation
Time Frame: 6-24 months
|
Survival without amputation (survival without whole amputation including minor and major amputation) for 6, 12, and 24 months after operation
|
6-24 months
|
device success
Time Frame: during index procedure
|
definition of device success : Successful guide, inflation, deflation, and withdrawal of the Passeo-18 Lux Paclitaxel releasing balloon catheter
|
during index procedure
|
Technical success
Time Frame: during index procedure
|
definition of technical success : Finished vascular procedure successfully and achieved ≤50% residual stenosis rate when assessing under visual inspection immediately after operation
|
during index procedure
|
Success in operation
Time Frame: during index procedure
|
definition of op : Defined it as the case that technical success and device success were achieved and no MAE occurred during the index procedure period.
|
during index procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Je Hwan Won, MD, Korean Society of Interventional Radiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Vascular Diseases
- Peripheral Arterial Disease
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- AJIRB-DEV-DE4-17-478
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioplasty, Balloon
-
French Cardiology SocietyRecruitingAngioplasty | Lithotripsy | Coronary BalloonFrance
-
Vienna General HospitalCompletedInstent Restenosis | Cutting Balloon AngioplastyAustria
-
Liyuan Hospital of Tongji Medical College, Huazhong...First People's Hospital of Hangzhou; RenJi Hospital; Chengdu University of Traditional... and other collaboratorsActive, not recruitingDrug-coated Balloon | Angioplasty | Femoropopliteal Artery OcclusionChina
-
University Hospital, BordeauxUnknown
-
Chonbuk National University HospitalUnknownAngioplasty, Balloon, CoronaryKorea, Republic of
-
Fatebenefratelli and Ophthalmic HospitalCompletedPercutaneous Coronary Intervention | Angioplasty, Balloon, Coronary | Arteriosclerosis, Coronary | Coronary Angioplasty, Transluminal BalloonItaly
-
Instituto Nacional de Cardiologia Ignacio ChavezGSE Biomedical; Medstent SA de CV.WithdrawnCoronary Artery Disease | Stents | Treatment Outcome | Coronary Angiography | Angioplasty, Balloon, Coronary | Angioplasty | HumansMexico
-
Shanghai Zhongshan HospitalUnknownCoronary Occlusion | Angioplasty, Balloon, Coronary
-
iVascular S.L.U.RecruitingPeripheral Arterial Disease | Angioplasty | Paclitaxel | Drug-eluting Balloon | Femoral ArteryFrance
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; B. Braun Korea Co., Ltd.RecruitingCoronary Artery Disease | Angioplasty, BalloonKorea, Republic of
Clinical Trials on Passeo-18 Lux Paclitaxel releasing Balloon Catheter
-
Biotronik AGCompletedArteriosclerosis | Atherosclerosis | Peripheral Artery Disease | Vascular DiseaseBelgium, Austria, Germany
-
Biotronik AGCompletedArteriosclerosis | Atherosclerosis | Peripheral Artery Disease | Vascular DiseaseGermany, Austria
-
Flanders Medical Research ProgramCompletedPeripheral Vascular DiseaseBelgium
-
Biotronik AGCompleted
-
Singapore General HospitalUnknownHemodialysis Access Failure | Dialysis Access Malfunction | Arterio-venous Fistula | Arteriovenous Graft StenosisSingapore
-
Centre hospitalier de l'Université de Montréal...Biotronik Canada IncCompletedArteriovenous Graft | Arteriovenous FistulaeCanada
-
Singapore General HospitalCompletedBrachiocephalic Vein StenosisSingapore
-
ID3 MedicalActive, not recruitingPeripheral Arterial DiseaseBelgium, Austria, France, Switzerland
-
Biotronik AGCompletedAtherosclerosis | Peripheral Artery DiseaseFrance, Germany, Spain, Belgium, Singapore, Austria, Netherlands, Malaysia, Italy, Switzerland, Denmark, Portugal, Australia, Finland, Latvia, Slovakia